GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (WBO:MDG1) » Definitions » Deferred Policy Acquisition Costs

Medigene AG (WBO:MDG1) Deferred Policy Acquisition Costs


View and export this data going back to 2017. Start your Free Trial

What is Medigene AG Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Medigene AG (WBO:MDG1) Business Description

Industry
Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.